As of October 2021, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a global emergency, and novel therapeutics are urgently needed. Here we describe human single chain variable fragment (scFv) antibodies (76clAbs) that block an epitope of the SARS-CoV-2 spike protein essential for ACE2-mediated entry into cells. 76clAbs neutralize the delta variant and other variants being monitored (VBMs) and inhibit spike-mediated pulmonary cell-cell fusion, a critical feature of COVID-19 pathology. In two independent animal models, intranasal administration counteracted the infection. Due to high efficiency, remarkable stability, resilience to nebulization and low production cost, 76clAbs may become a relevant tool for rapid, self-administrable early intervention in SARS-CoV-2-infected subjects independently of their immune status.

Human inhalable antibody fragments neutralizing {SARS}-{CoV}-2 variants for {COVID}-19 therapy / O. Minenkova, D. Santapaola, F. Maria Milazzo, A. Maria Anastasi, G. Battistuzzi, C. Chiapparino, A. Rosi, G. Gritti, G. Borleri, A. Rambaldi, C. Dental, C. Viollet, B. Pagano, L. Salvini, E. Marra, L. Luberto, A. Rossi, A. Riccio, E. Merlo Pich, M. Gabriella Santoro, R. De Santis. - (2021 Oct 15). [10.1101/2021.06.04.447066]

Human inhalable antibody fragments neutralizing {SARS}-{CoV}-2 variants for {COVID}-19 therapy

A. Rambaldi;
2021-10-15

Abstract

As of October 2021, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a global emergency, and novel therapeutics are urgently needed. Here we describe human single chain variable fragment (scFv) antibodies (76clAbs) that block an epitope of the SARS-CoV-2 spike protein essential for ACE2-mediated entry into cells. 76clAbs neutralize the delta variant and other variants being monitored (VBMs) and inhibit spike-mediated pulmonary cell-cell fusion, a critical feature of COVID-19 pathology. In two independent animal models, intranasal administration counteracted the infection. Due to high efficiency, remarkable stability, resilience to nebulization and low production cost, 76clAbs may become a relevant tool for rapid, self-administrable early intervention in SARS-CoV-2-infected subjects independently of their immune status.
Settore MED/10 - Malattie dell'Apparato Respiratorio
https://www.biorxiv.org/content/10.1101/2021.06.04.447066v2.full.pdf+html
File in questo prodotto:
File Dimensione Formato  
2021.06.04.447066v2.full.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 687.86 kB
Formato Adobe PDF
687.86 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/903753
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact